Lifecore Biomedical, Inc. (LFCR) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $5.20. It has a SharesGrow Score of 40/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of LFCR = $1.98 (-61.9% from the current price, the stock appears overvalued). Analyst consensus target is LFCR = $7 (+25% upside).
Valuation: LFCR trades at a trailing Price-to-Earnings (P/E) of -4.6 (S&P 500 average ~25).
Financials: revenue is $129M, -6.6%/yr average growth. Net income is $39M (loss), growing at -144.1%/yr. Net profit margin is -30% (negative). Gross margin is 31.3% (+4.1 pp trend).
Balance sheet: total debt is $131M against $1M equity (Debt-to-Equity (D/E) ratio 97.92, leveraged). Current ratio is 2.84 (strong liquidity). Debt-to-assets is 54.7%. Total assets: $239M.
Analyst outlook: 5 / 7 analysts rate LFCR as buy (71%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 75/100 (Pass), Growth 15/100 (Fail), Past 25/100 (Fail), Health 33/100 (Fail), Moat 44/100 (Fail), Future 79/100 (Pass), Income 10/100 (Fail).
